Supply Chain

In order to provide both profitability and medication access, a balancing act is required.

A look at the challenges that need to be addressed during the FDA stabilization period.

Under the DSCSA law, wholesale distributors, re-packagers, dispensers, and other third-party logistics providers must implement interoperable and electronic tracing of prescription products at the package level.

As a result, time to treatment for the brand Gilead product is expected to increase from 16 to 14 days.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

One lot of the company’s branded dextroamphetamine sulfate tablets is being removed from shelves nationwide due to a pharmacy receiving carbinoxamine maleate instead.

The predicted value is largely driven by manufacturers' prioritization of brand protection.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

IATA’s latest numbers suggest the strongest year-on-year growth in almost two years.

The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.

Review article explores the latest developments surrounding expression and purification strategies.

The latest move expands the company’s storage capacity and cold chain capabilities.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.

MoU aims to align the pharmaceutical and cold chain sectors by boosting operations.

The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.

Conference keynote offers an industry outlook, including new commercialization challenges.

The rise in demand represents the third consecutive month of year-on-year growth.

Back in Boston, Pharma Commerce tackles all things logistics at LogiPharma USA.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

What stands between pharma and other industries when it comes to remaining vigilant?

The companies will partner up to design and implement solutions that support each other's business efforts.

Biden Administration invokes Defense Production Act to facilitate domestic manufacturing of essential medicines.

Studies explore how both the UK and EU are handling these ongoing supply chain challenges.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.

IATA numbers point to continuing recovery.

Purchase grows the company’s CRYOPDP domestic footprint while strengthening working relationship between both parties.